Icatibant Gp Pharm

Icatibant, the active ingredient in Icatibant Gp Pharm, is a bradykinin B2 receptor antagonist presented as a sterile subcutaneous injection solution for subcutaneous use. It provides rapid relief of swelling during acute attacks of hereditary angioedema in patients who lack functional C1 inhibitor.

GNH USA supplies Icatibant Gp Pharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is indicated for the treatment of hereditary angioedema, a condition driven by uncontrolled bradykinin activity.

- Acute hereditary angioedema attacks: rapid reduction of swelling and associated pain during HAE episodes. - Hereditary angioedema (C1‑INH deficiency): on‑demand therapy to halt progression of edema when an attack begins.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin redness. - Swelling at injection site: transient edema. - Pruritus: itching around the injection area. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema: unexpected swelling of face, lips, or throat. - Hypotension: sudden drop in blood pressure. - Thrombocytopenia: low platelet count observed rarely. - Severe injection site necrosis: tissue death at injection site (rare).

When using Icatibant, several precautions should be observed to ensure safe and effective therapy. - Pregnancy: safety not established; prescribe only if potential benefit justifies risk. - Breastfeeding: unknown excretion; use with caution. - Renal impairment: no dosage adjustment required, but monitor for accumulation. - Concomitant ACE inhibitors or neprilysin inhibitors: may increase bradykinin levels; observe for angioedema. - Hypersensitivity: discontinue immediately if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or affect injection site reactions.

Major Interactions (Avoid): - ACE inhibitors: combined effect on bradykinin may raise risk of angioedema. - Neprilysin inhibitors (e.g., sacubitril): potentiate bradykinin activity, increasing swelling risk.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may modestly raise bradykinin levels; monitor for edema. - Other subcutaneous biologics: potential for injection site irritation; rotate sites. - Antihistamines: may mask early signs of allergic reaction; observe patient closely.